within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH51_SitagliptinAndSimvastatin;
model SitagliptinAndSimvastatin 
   extends Pharmacolibrary.Drugs.ATC.A.A10BH51;

  annotation(Documentation(
    info ="<html><body><p>Sitagliptin and simvastatin is a fixed-dose combination drug approved for use in the management of type 2 diabetes mellitus and dyslipidemia. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for improving glycemic control, while simvastatin is a HMG-CoA reductase inhibitor (statin) used to lower cholesterol and reduce cardiovascular risk. This combination allows for convenient co-administration to patients requiring both glycemic and cholesterol management.</p><h4>Pharmacokinetics</h4><p>No published population pharmacokinetic parameters are available specifically for the fixed-dose combination of sitagliptin and simvastatin (ATC A10BH51). Below are estimated parameters based on available data for the individual monotherapies in healthy adults receiving typical oral doses.</p><h4>References</h4><ol><li><p>Steinberg, H, et al., &amp; Engel, SS (2013). Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. <i>Vascular health and risk management</i> 9 273–282. DOI:<a href=&quot;https://doi.org/10.2147/VHRM.S44330&quot;>10.2147/VHRM.S44330</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23761972/&quot;>https://pubmed.ncbi.nlm.nih.gov/23761972</a></p></li><li><p>Burugula, L, et al., &amp; Kandhagatla, R (2013). Simultaneous determination of sitagliptin and simvastatin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. <i>Biomedical chromatography : BMC</i> 27(1) 80–87. DOI:<a href=&quot;https://doi.org/10.1002/bmc.2751&quot;>10.1002/bmc.2751</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22544712/&quot;>https://pubmed.ncbi.nlm.nih.gov/22544712</a></p></li><li><p>Pham, DQ, et al., &amp; Plakogiannis, R (2008). Sitagliptin: a novel agent for the management of type 2 diabetes mellitus. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 65(6) 521–531. DOI:<a href=&quot;https://doi.org/10.2146/ajhp070248&quot;>10.2146/ajhp070248</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18319497/&quot;>https://pubmed.ncbi.nlm.nih.gov/18319497</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end SitagliptinAndSimvastatin;
